IRTA Webinar - October 19, 2021

Disease-modifying therapy in short bowel syndrome

Tuesday, October 19, 2021, 2:00 PM (Local time in Montreal)
Local time (Corresponding local time at your current location)

Overview

Short-bowel syndrome is the most common cause of intestinal failure. Until recently, management options were limited to dietary support, anti-secretory drugs and anti-motility agents. The introduction of GLP-2 analogues have drastically changed the field, offering disease-modifying therapy which can lead to reduction of parenteral support. However, several questions remain: which is the ideal target population? When should treatment be started? Can the treatment frequency be reduced after full weaning? And how should the care for a patient treated with GLP-2 analogues be embedded in a multidisciplinary approach?

Learning Objectives

  1. To understand the mechanism of action of GLP-2 analogues in short-bowel syndrome.
  2. To know the expected clinical effects and adverse events during treatment with GLP-2 analogues.
  3. To know the predictors of response to GLP-2 analogues.
  4. To understand the multidisciplinary management of a patient treated with GLP-2 analogues.
Tim Vanuytsel
Moderator
Leuven University Hospital
Belgium
Bio
Palle Bekker Jeppesen
Presenter
Department of Intestinal Failure and Liver Diseases, Rigshospitalet
Denmark
Bio
Francisca Joly 
Presenter
Beaujon Hospital – University of Paris
France
Bio

Use the image below to promote this event (right-click to download)

Social

Contact

Staff Directory
+1-514-874-1717 ,X : 216
sections@tts.org

Address

Intestinal Rehabilitation & Transplant Association
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada